Features of high-dose intravenous immunotherapy administration in patients with reduced IgA level in neurological practice: literature review and description of a clinical case

Intravenous high-dose immunotherapy is one of the highly effective proven treatments for a number of autoimmune diseases of the nervous system. Nowadays there is enough knowledge about the spectrum of side effects and approaches to their prevention and monitoring. Most of them are leveled by improving the technology of the production process, but anaphylactic reactions remain one of the uncontrolled, albeit rare, undesirable reactions. The development of allergic reactions is associated with the presence of antibodies to immunoglobulin class A (IgA) in the patient, which is manifested by a decrease in the level of IgA during routine immunological examination. The article provides a review of the literature on the prevalence of IgA deficiency, its causes. A modern view of the need for routine testing of IgA level before the course of intravenous immunotherapy, approaches to reduce the risk of developing serious adverse reactions in such cases is described. A clinical case of treatment of a patient with chronic inflammatory demyelinating polyneuropathy and a reduced level of IgA is presented.

intravenous immunotherapy, side effect, adverse event, anaphylactic reaction, hypo-IgA, prevention

1. Lünemann J. D., Nimmerjahn F., Dalakas M. C. Intravenous immunoglobulin in neurology – mode of action and clinical efficacy. Nat Rev Neurol 2015;11(2):80. DOI: 10.1038/ nrneurol.2014.253. PMID: 25561275.

2. Perez E. E., Orange J. S., Bonilla F. et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017;139(3):S1– S46. DOI: 10.1016/j.jaci.2016.09.023. PMID: 28041678.

3. Gelfand E. W. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Mede 2012;367(21): 2015–25. DOI: 10.1056/NEJMra1009433. PMID: 23171098.

4. Lünemann J. D., Quast I., Dalakas C. M. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics 2016;13(1):34–46. DOI: 10.1007/s13311-015-0391-5. PMID: 26400261.

5. Suponeva N. A., Piradov M. A. Intravenous immunotherapy in neurology. Moscow: Goryachaya liniya-Telekom, 2013.(In Russ.).

6. Elovaara I., Apostolski S., van Doorn P. et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases (2008). Eur J Neurol 2008;15(9):893–908. DOI: 10.1111/j.1468-1331.2008.02246.x. PMID: 18796075.

7. Suponevа N. А., Piradov М. А. Peculiarities of the intravenous therapy in the neurologic clinic. Effektivnaya farmakoterapiya = Efficient Pharmacotherapy 2014;(6): 36–43. (In Russ.).

8. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics: targets & therapy 2012;6:277. DOI: 10.2147/BTT. S25188.

9. Rachid R., Castells M., CunninghamRundles C., Bonilla F. A. Association of anti-IgA antibodies with adverse reactions to γ-globulin infusion. J Allergy Clin Immunol 2011;128(1):228–30. DOI: 10.1016/j.jaci.2011.01.061. PMID: 21397310.

10. Rachid R., Bonilla F. A. The role of antiIgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012;129(3):628–34. DOI: 10.1016/j. jaci.2011.06.047. PMID: 21835445.

11. Cunningham-Rundles C. Physiology of IgA and IgA deficiency. J Clin Immunol 2001;21(5):30–9. DOI: 10.1023/ A:1012241117984. PMID: 11720003.

12. Yel L. Selective IgA deficiency. J Clin Immunol 2010;30(1):10–6. DOI: 10.1007/s10875-009-9357-x. PMID: 20101521.

13. Latiff A. H., Kerr M. A. The clinical significance of immunoglobulin A deficiency. Ann Clin Biochem 2007;44(2):131–9. DOI: 10.1258/000456307780117993. PMID: 17362578.

14. Bonilla F. A., Bernstein I. L., Khan D. A. et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94(50):S1–S63. DOI: 10.1016/ s1081-1206(10)61142-8. PMID:15945566.

15. WHO Scientific Group. Primary immunodeficiency diseases: report of a WHO scientific group. Clin Exp Immunol 1997;109(1):1–28. PMID: 9274617.

16. Bocharova K. A. Diagnostics and management of primary immuno deficiency disease: The selective IgA deficiency. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Meditsina. Farmatsia: Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy 2012;4(123):259–65. (In Russ.).

17. Lilic D., Sewell W. A. IgA deficiency: what we should – or should not – be doing. J Clin Pathol 2001;54(5):337–8. DOI: 10.1136/jcp.54.5.337. PMID: 11328829.

18. Sandler S. G., Eckrich R., Malamut D., Mallory D. Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions. Blood 1994;84(6):2031–5. PMID: 8081004.

19. Vyas G. N., Perkins H. A., Fudenberg H. H. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet 1968;2(7563):312–5. PMID: 4173734.

20. Vyas G. N., Perkins H. A., Yang Y. M., Basantani G. K. Healthy blood donors with selective absence of immunoglobulin A: prevention of anaphylactic transfusion reactions caused by antibodies to IgA. J Lab Clin Med 1975;85(5):838–42. PMID: 804531.

21. Ferreira A., Garcia Rodriguez M. C., Lopez-Trascasa M. et al. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with γ-globulin. Clin Immunol Immunopathol 1988;47(2):199–207. DOI: 10.1016/0090-1229(88)90072-4. PMID: 2450712.

22. Stiehm E. R. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013;27(3):171–8. DOI: 10.1016/j.tmrv.2013.05.004. PMID: 23835249.

23. Suponeva N. A., Grishina D. A. Intravenous high-dose immunotherapy: practical recommendations for use in the treatment of neurological disimmune diseases. Nervno-myshechnye bolezni = Neuromuscular Diseases 2015;5(4):16–23. (In Russ.).

24. Suponevа N. А., Naumovа E. S., Gnedovskaya E. V. Chronic inflammatory demyelinating polyneuropathy in adults: diagnostic approaches and first line therapy. Nervnomyshechnye bolezni = Neuro muscular Diseases 2016;6(1):44–53. (In Russ.).

25. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29(3):173–84. DOI: 10.1385/CRIAI:29:3:173. PMID: 16391392.

26. Bonilla F. A. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008;122(6):1238–9. DOI: 10.1016/j.jaci.2008.08.033. PMID:18842292.

27. Björkander J., Hammarström L., Smith C. I. et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987;7(1):8–15. DOI: 10.1007/ bf00915419. PMID: 3494039.

28. Eijkhout H. W., van den Broek P. J., van Der Meer J. W. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003;61(6):213–7. PMID: 12948165.

29. Sundin U., Nava S., Hammarström L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112(2):341–6. DOI: 10.1046/j.1365-2249.1998.00571.x. PMID: 9649200.

30. Piradov M. A., Suponeva N. A. Use of intravenous immunoglobulins in treatment of neuromuscular disorders. Immunoglobulins for intravenous administration: practical aspects of use. Eds. A. G. Rumyantsev, A. Yu. Scherbina. Moscow: Prakticheskaya Meditsina, 2018. P. 166–2010. (In Russ.).

31. Léger J. M., De Bleecker J. L., Sommer C. et al. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study(the PRIMA study). J Peripher Nerv Syst 2013;18(2):130–40. DOI: 10.1111/jns5.12017. PMID: 23781960.